About NextGen Peptides — Metabolic & Weight Research Digest
What this desk is
NextGen Peptides is an independent research digest focused on a specific slice of metabolic pharmacology: the incretin-class peptides studied for weight management and metabolic regulation. It is not a store, not a clinic, and not affiliated with any pharmaceutical manufacturer.
The three compounds covered — semaglutide, tirzepatide, and retatrutide — represent a pharmacological progression that has moved faster than almost any drug class in recent memory. Each adds a receptor target; each, so far, has produced larger weight-loss numbers in trials than the one before it. That progression is the organizing logic of this desk.
How this desk reads the literature
Every quantitative claim on this site carries a citation number that maps to the shared references list. Effect sizes are reported as the primary trials measured them: percentage body-weight change from baseline, hazard ratios with confidence intervals, HbA1c absolute reductions. Study design is flagged — Phase 2 versus Phase 3, open-label versus blinded, industry-sponsored versus independent — because those distinctions matter when interpreting the numbers.
Where known safety signals exist, they receive the same treatment as efficacy data: sourced, quantified where possible, and characterized at the resolution the evidence supports. A safety finding from a pooled meta-analysis of nine RCTs (tirzepatide gallbladder risk, RR 1.97) is described differently from a theoretical mechanistic concern. The goal is to maintain a consistent epistemic standard across the desk — not to make everything look reassuring or everything look alarming.
For the investigational compound (retatrutide), the Phase 2 data are presented alongside an explicit flag that Phase 3 has not reported and no regulatory review has occurred. Phase 2 numbers and Phase 3 numbers are not the same thing.
What this desk does not do
NextGen Peptides does not sell any product. It does not recommend any compound for any use. It does not provide or imply doses, preparation instructions, sourcing guidance, or medical advice. It does not evaluate gray-market or research-channel formulations, and it does not suggest that the compounds covered here are appropriate for unsupervised human use.
Semaglutide and tirzepatide are FDA-approved prescription medicines. Their evidence base was generated under clinical oversight with pharmaceutical-grade formulations. Research-channel material sold outside that pathway operates in a different regulatory and safety context. Retatrutide has no approved formulation at all.
The correct source of medical guidance on any of these compounds is a qualified healthcare provider.
Why effect sizes matter
One of the consistent patterns in popular coverage of weight-management drugs is that percentage weight-loss figures circulate without the context that makes them meaningful: what the baseline was, what the comparator showed, and what the study design can actually support.
A mean -20.9% body-weight reduction at 15 mg tirzepatide in SURMOUNT-1 is a real and large effect [10]. But it is also a Phase 3 number from a 72-week industry-sponsored trial in adults with obesity — not a figure that transfers automatically to different populations, different time horizons, or gray-market formulations. The same discipline applies to the retatrutide Phase 2 data: the -24.2% at 48 weeks is the largest weight-loss number published from any pharmacological compound in a controlled trial [15], and it comes with a Phase 3 program still running.
This desk's job is to present those numbers honestly, with their denominator.